Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ANGLE establishes co-marketing agreement with leading molecular testing solutions provider QIAGEN

The AIM-listed liquid biopsy firm said the partnership will “seek to leverage the advantages of combining ANGLE's world leading Parsortix system for harvesting circulating tumor cells (CTCs) with QIAGEN's liquid biopsy solution portfolio"
Cancer cell
The group said the initial focus will be on prostate and breast cancer research applications

ANGLE PLC (LON:AGL) saw its shares jump higher this morning on news the liquid-biospy firm has established a co-marketing agreement with QIAGEN NV, a world-leading provider of molecular testing solutions.

The AIM-listed group said the partnership will “seek to leverage the advantages of combining ANGLE's world leading Parsortix system for harvesting circulating tumor cells (CTCs) with QIAGEN's liquid biopsy solution portfolio which consists of dedicated NGS (next generation sequencing), PCR (polymerase chain reaction), single cell analysis products and bioinformatics capabilities.”

READ: ANGLE says research further demonstrates key advantages of Parsortix system for cancer treatment

The group said the initial focus will be on prostate and breast cancer research applications.

It added that the agreement entails both companies offering the other's products to its customer base and follows an intensive evaluation of Parsortix by QIAGEN identifying the advantages of the system.

QIAGEN, which is headquartered in Germany, has more than 500,000 customers in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharma and biotech companies) and Academia (life sciences research).

Andrew Newland, ANGLE’s founder and chief executive, said: “We believe the ability to offer customers a combination of Parsortix with validated and reliable downstream analysis technologies from a world leader such as QIAGEN facilitates key aspects of the sales cycle and we look forward to working closely together.”

He added: “Partnering is a core part of ANGLE's strategy to secure widespread adoption of Parsortix right across the market leveraging the customer base and distribution channels of established players."

In early morning trading, ANGLE shares were nearly 7%, or 2.25p higher at 34.75p.

In a note to clients, analysts at finnCap said: “No changes to forecasts, although we argue that this partnership should provide upside, and retain our 100p price target.”

 -- Adds share price, broker comment --

 

View full AGL profile View Profile

ANGLE plc Timeline

Newswire
October 12 2017

Related Articles

Antibiotics
October 04 2017
US Food & Drug administration approval is yet to be granted but iclaprim, which has fast-track status, is closing in on the promised land.
test tubes filled with blood
November 02 2017
In all, 116 of the 200 patients with the life-threatening auto-immune disease have been through the 52-week process looking at the efficacy of Lupuzor
Woman with tissue facing pollen
October 20 2017
Allergy, which saw its market share grow by a percentage point to 13%, is in a strong financial position, with £22.1mln in the bank

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use